These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18095908)

  • 1. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A; Abrams CS
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
    Arnold DM; Nazi I; Kelton JG
    Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
    Vadhan-Raj S
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of thrombopoietic agents in the treatment of thrombocytopenia.
    Kobos R; Bussel JB
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):33-43. PubMed ID: 18501086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the potential for thrombopoietic agents in acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
    Levy B; Arnason JE; Bussel JB
    Curr Opin Oncol; 2008 Nov; 20(6):690-6. PubMed ID: 18841052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
    Kuter DJ
    Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 15. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
    Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
    J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim: a second-generation thrombopoietin agonist.
    Cohn CS; Bussel JB
    Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 19. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
    Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
    Matzdorff A; Giagounidis A; Greinacher A; Hiller E; Kiefel V; Müller-Beissenhirtz H; Ostermann H; Rummel M; Sachs UJ; Salama A
    Onkologie; 2010; 33 Suppl 3():2-20. PubMed ID: 20484949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.